Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer.

Find People
Find Everything
About This Site
Edit My Profile
Login to Profiles
DIRECT2Experts
Help / FAQ

Announcement

You can now add alternative names! Click here to add other names that you've published under.

Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer.

Makhoul I, Klimberg VS, Korourian S, Henry-Tillman RS, Siegel ER, Westbrook KC, Hutchins LF. Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer. Am J Clin Oncol. 2015 Feb; 38(1):74-9.

View in: PubMed

subject areas

Adult
Aged
Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Carcinoma
Carcinoma, Ductal, Breast
Carcinoma, Lobular
Cyclophosphamide
Female
Humans
Lymph Nodes
Mastectomy
Mastectomy, Segmental
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Prospective Studies
Receptors, Estrogen
Receptors, Progesterone
Retrospective Studies
Taxoids
Treatment Outcome

authors with profiles

Ronda Henry-Tillman
Kent Westbrook
Soheila Korourian